Hereditary Spastic Paraplegia 7 (SPG7) — Comprehensive Disease Research Report

1. Disease Information

Overview. Hereditary Spastic Paraplegia 7 (SPG7; also called SPG7-related neurologic disorder) is an autosomal recessive neurodegenerative disorder caused by biallelic pathogenic variants in SPG7, which encodes the mitochondrial inner-membrane m-AAA protease subunit paraplegin. It is the first-identified autosomal recessive form of hereditary spastic paraplegia (HSP) and one of the most common causes of autosomal recessive HSP and spastic ataxia, accounting for roughly 5–12% of AR-HSP cases. The classic presentation is slowly progressive bilateral lower-limb spasticity and weakness from corticospinal tract axonal degeneration, but SPG7 is now recognized as a broad phenotypic spectrum encompassing uncomplicated spastic paraplegia, complicated spastic ataxia, isolated cerebellar/spinocerebellar ataxia, isolated optic atrophy, chronic progressive external ophthalmoplegia (PEO), and other presentations (GeneReviews, NCBI Bookshelf NBK1107).

Key identifiers: - OMIM: #607259 (Spastic Paraplegia 7, Autosomal Recessive); gene locus OMIM #602783 (SPG7 Matrix AAA Peptidase Subunit, Paraplegin) (OMIM #607259; OMIM #602783) - Gene location: Chromosome 16q24.3 - GeneReviews: SPG7-Related Neurologic Disorder (NBK1107) - GARD/NIH Rare Disease listing: Hereditary spastic paraplegia 7 - GTR condition record: C1846564 - Reference transcript: NM_003119 (used for HGVS variant nomenclature in ClinVar)

Synonyms/alternative names: Spastic paraplegia 7, autosomal recessive; SPG7-related disorder; hereditary spastic ataxia-7; paraplegin deficiency; SPG7 spastic ataxia; autosomal recessive spastic ataxia with optic atrophy (in some phenotype descriptions).

Evidence base. Information derives primarily from aggregated cohort/disease-level resources (GeneReviews expert-curated summaries drawing on the international cohort of Coarelli et al. 2019 [n=241], OMIM, and case series/registries), not raw individual-level EHR data. Molecular/mechanistic data derive from model-organism (mouse, Drosophila) and patient-derived iPSC/fibroblast studies.

2. Etiology

Disease Causal Factors

SPG7 is a monogenic mitochondrial disorder. Biallelic (homozygous or compound heterozygous) loss-of-function or missense pathogenic variants in SPG7 impair the m-AAA protease, causing progressive degeneration of the longest corticospinal and cerebellar axons — a length-dependent "dying-back" axonopathy driven by mitochondrial dysfunction and impaired axonal transport (see Mechanism, §6).

Risk Factors

• Genetic risk factors:
• Causal biallelic variants in SPG7 (>100 reported pathogenic variants: missense, nonsense, frameshift, splice-site, and rare deletion/duplication CNVs).
• p.Ala510Val (c.1529C>T) is the single most prevalent pathogenic allele, with a reported carrier frequency up to ~1% in the general population — making it a common "hypomorphic" variant that frequently appears in trans with a second, more severe allele, and occasionally appears to act as a low-penetrance dominant risk allele.
• p.Leu78Ter (c.233T>A), a nonsense variant in exon 2, was the most frequent variant in a Hungarian cohort (Frontiers Genetics, PMC12215234), with gnomAD minor allele frequency 0.0028 in South Asians (5 homozygotes reported).
• Compound heterozygosity/consanguinity in populations with elevated consanguinity rates increases homozygosity risk.
• Heterozygous monoallelic SPG7 variants have been reported as possible risk/modifier alleles for amyotrophic lateral sclerosis (ALS), and digenic heterozygosity with AFG3L2 (the paralogous m-AAA subunit) causes a distinct motor-neuron/cerebellar disorder (see below).
• Environmental/demographic risk factors: None specifically established; disease is fully genetically determined, though age (onset window 20–40, mean 35.5 ± 14.3 years; range infancy to age 72) modifies symptom expression.
• Protective factors: None specifically documented in the literature reviewed; no known protective genetic modifiers or lifestyle protective factors are established.
• Gene-environment interactions: Not established for SPG7; disease penetrance and severity appear driven by variant type (loss-of-function vs. missense) rather than documented environmental modifiers.

3. Phenotypes

Frequencies below are drawn from the international GeneReviews-cited cohort (Coarelli et al. 2019, n=241), reported at first and follow-up ("second") examination, reflecting disease progression over time:

Phenotype spectrum categories (GeneReviews): uncomplicated spastic ataxia, complicated spastic ataxia, spinocerebellar ataxia, and isolated optic nerve atrophy — the boundaries between these presentations are not fixed, and spasticity and ataxia can occur "in isolation, at the same time, or sequentially," with most patients eventually developing both.

Age of onset: Mean 35.5 ± 14.3 years (typically 20–40 years), but ranges from infancy to age 72.

Progression: Insidious, slowly progressive. Roughly one-third of individuals show severe gait abnormality within 8–10 years of onset; some become wheelchair-dependent.

Quality of life impact: A cerebello-cortical connectivity study found cognitive and social/behavioral deficits (e.g., disturbed attention, executive function, emotional communication impairment) linked to cerebellar-cortical circuit alterations in SPG7 patients (PMC7053515). Progressive mobility loss, dysphagia risk (aspiration), visual impairment, and bladder dysfunction compound cumulative disability and reduced independence over the disease course.

4. Genetic/Molecular Information

Causal gene: SPG7 (HGNC gene symbol SPG7; protein: paraplegin), chromosome 16q24.3, OMIM gene entry #602783.

Variant classification and types: - >100 reported pathogenic/likely pathogenic variants (ClinVar, HGMD): missense, nonsense, frameshift, splice-site, and rare deletion/duplication CNVs. - Detection rates: sequence analysis (missense/nonsense/small indel/splice) detects >90% of pathogenic alleles; gene-targeted deletion/duplication analysis (qPCR, long-range PCR, MLPA, targeted microarray) detects <10% of the remainder. - Deep intronic/non-coding variants missed by exome sequencing have been identified via genome sequencing, explaining some cases with only one variant found by exome (PMC12883507 — "Identification of an additional deep intronic splice variant prompts critical evaluation of SPG7 inheritance").

Recurrent/founder variants: - p.Ala510Val (c.1529C>T) — most common pathogenic allele overall; population carrier frequency up to ~1%; associated with a cerebellar-ataxia-predominant phenotype and slightly later onset; frequently found as compound heterozygote or in apparent pseudodominant pedigrees. - p.Leu78Ter (c.233T>A) — nonsense/loss-of-function variant, most common in a Hungarian cohort; associated with more severe, spasticity/pyramidal-and-optic-atrophy–predominant phenotype (loss-of-function genotype-phenotype correlation).

Genotype-phenotype correlation: Biallelic loss-of-function variants correlate with more pronounced pyramidal signs and optic atrophy; individuals carrying at least one missense allele (especially p.Ala510Val) tend to show more pronounced ataxia relative to spasticity.

Population/allele frequency databases: gnomAD, 1000 Genomes, ExAC/TOPMed for carrier-frequency and homozygote counts (e.g., p.Leu78Ter MAF 0.002778 in South Asian gnomAD subpopulation, 5 homozygotes).

Functional consequences: Loss of paraplegin function impairs the mitochondrial m-AAA protease quality-control complex (formed with AFG3L2), causing reduced Complex I respiratory chain activity, defective processing of mitochondrial substrates (e.g., MRPL32, EMRE), and dysregulated mitochondrial calcium handling via altered MCU-EMRE assembly and the mitochondrial permeability transition pore (mPTP) (Cell Research review, PMC5835776).

Modifier genes / digenic interaction: AFG3L2 — the paralogous m-AAA protease subunit (mutated in autosomal dominant SCA28) — physically and functionally interacts with paraplegin. A 2025 study (medRxiv/BMC Medicine) found digenic combined heterozygosity in SPG7 + AFG3L2 in patients with motor neuron disease and cerebellar ataxia phenotypes: among 4,817 MND/ataxia patients, 6 carried digenic variants (none among 1,827 controls); segregation in families was perfect; animal models with combined dysfunction of both genes show early-onset axonal degeneration and prominent Purkinje cell loss (BMC Medicine 2025; medRxiv preprint).

Epigenetic information: No disease-specific epigenetic (DNA methylation/histone) mechanism has been established for SPG7 in the literature reviewed.

Chromosomal abnormalities: SPG7 is caused by point mutations/small indels, not large chromosomal rearrangements; no recurrent CNV/aneuploidy syndrome association identified.

Mitochondrial genome consequence (secondary): Pathogenic SPG7 variants cause secondary mitochondrial DNA instability — multiple mtDNA deletions accumulate in postmitotic tissue (skeletal muscle), analogous to POLG-related disorders, due to disordered mtDNA maintenance (Brain 2014, Hudson lab study). Single-fiber molecular studies show multiple mtDNA deletions segregating at 38–97% heteroplasmy in COX-deficient muscle fibers (PMC3899233).

5. Environmental Information

No established environmental, lifestyle, or infectious causal or exacerbating factors are documented for SPG7 in the literature surveyed — it is a fully genetically determined mitochondrial disorder. No infectious agents are implicated. Systemic mitochondrial-toxic environmental exposures have not been specifically studied as modifiers of SPG7 severity, though caution around known mitochondrial-toxic drugs (e.g., certain antiretrovirals, statins in some mitochondrial disease contexts) may be prudent extrapolation from general mitochondrial disease management principles, not SPG7-specific evidence.

6. Mechanism / Pathophysiology

Molecular function of paraplegin. Paraplegin is the catalytic ATP-dependent metalloprotease subunit of the mitochondrial inner-membrane m-AAA protease complex, forming a hetero-oligomer with AFG3L2. This complex: 1. Performs mitochondrial protein quality control — degrading misfolded polypeptides and unassembled proteins on the matrix side of the inner mitochondrial membrane. 2. Carries out proteolytic maturation of specific substrates, including ribosomal protein MRPL32 (required for mitochondrial ribosome assembly/translation) and EMRE (a component of the mitochondrial calcium uniporter, MCU). 3. Regulates mitochondrial calcium homeostasis, limiting MCU-EMRE complex assembly and thereby modulating opening of the mitochondrial permeability transition pore (mPTP) — a key determinant of cell death susceptibility (Cell Research, PMC5835776).

Causal chain (trigger → consequence): 1. Biallelic SPG7 loss-of-function/missense variant → loss of functional m-AAA protease (paraplegin-AFG3L2 complex). 2. → Reduced mitochondrial Complex I respiratory chain activity and impaired mitoribosomal protein maturation (MRPL32 processing failure). 3. → Mitochondrial calcium dysregulation (via defective EMRE processing / MCU-EMRE control) and increased mPTP susceptibility. 4. → Secondary mitochondrial genome instability — accumulation of multiple mtDNA deletions in postmitotic tissues (muscle, neurons), producing COX-deficient, ragged-red fibers. 5. → Mitochondrial morphological abnormalities — swollen, dysmorphic mitochondria appearing first in distal axons and synaptic terminals, well before axonal swelling (mouse model: swollen mitochondria at 4.5 months, axonal swelling at 8 months, degeneration at 15 months — JCI, Ferreirinha et al. 2004). 6. → Impaired axonal transport — anterograde transport impairment causes massive accumulation of organelles and neurofilaments within axonal swellings; retrograde transport is also delayed in symptomatic animals. 7. → Length-dependent ("dying-back") axonal degeneration — preferentially affecting the longest and largest-caliber axons: the corticospinal tract (causing spasticity), cerebellar afferent/efferent pathways (ataxia), and optic nerve (optic atrophy), because these neurons are most dependent on efficient long-distance axonal mitochondrial transport and energy supply. 8. → Clinical manifestation: progressive spastic paraparesis, cerebellar ataxia/dysarthria/dysphagia, optic atrophy, peripheral neuropathy, and (in a subset) PEO from muscle mtDNA deletion accumulation.

Cell types/tissues involved: upper motor neurons of corticospinal tract (Betz cells, axons), Purkinje cells and cerebellar circuitry, retinal ganglion cells/optic nerve axons, peripheral sensory/motor neurons, skeletal muscle fibers (secondary mitochondrial myopathy), and in digenic SPG7/AFG3L2 models, astrocytes (astrocyte-specific m-AAA protease deletion reveals a glial contribution to neurodegeneration — PMC6618114).

Suggested ontology terms: - GO biological process: GO:0034982 (mitochondrial protein processing), GO:0006515 (protein quality control for misfolded/incompletely synthesized proteins), GO:0051560 (mitochondrial calcium ion homeostasis), GO:0007005 (mitochondrion organization), GO:0008090 (retrograde axonal transport), GO:0008089 (anterograde axonal transport) - GO molecular function: GO:0004176 (ATP-dependent peptidase activity), GO:0004222 (metalloendopeptidase activity) - GO cellular component: GO:0005743 (mitochondrial inner membrane), GO:0031966 (mitochondrial membrane) - CL cell types: CL:0000029 (neuron, Betz cell / upper motor neuron equivalent), CL:0000121 (Purkinje cell), CL:0000740 (retinal ganglion cell), CL:0000187 (myocyte, skeletal muscle) - CHEBI: CHEBI:29108 (calcium(2+) ion) for the calcium-dysregulation arm

Molecular profiling / omics findings: Patient-derived iPSC neurons and fibroblasts show mitochondrial functional deficits specific to SPG7 (contrasted with SPAST-mutant HSP lines, which do not show comparable mitochondrial deficits) (PMC7469654). A 2023 high-throughput pharmacological rescue study in SPG7 patient-derived neurons identified compounds that reverse mitochondrial and neuronal phenotypic defects, supporting mitochondrial dysfunction as a druggable node (Frontiers in Neuroscience, PMC10520970).

7. Anatomical Structures Affected

Organ/system level: - Primary: Central nervous system — corticospinal tracts (spinal cord lateral columns), cerebellum (cortex, dentate nuclei, peduncles), optic nerve. - Secondary: Peripheral nervous system (sensorimotor peripheral nerves), skeletal muscle (secondary mitochondrial myopathy with COX-deficient/ragged-red fibers), extraocular muscles (in PEO variant), bladder (neurogenic dysfunction), skeletal system (secondary orthopedic deformity — pes cavus, scoliosis from chronic spasticity/imbalance), auditory system (sensorineural hearing loss in a subset). - Body systems: nervous system (primary), musculoskeletal, ophthalmologic, urologic.

Tissue/cell level: Corticospinal upper motor neuron axons (longest CNS axons, most vulnerable); cerebellar Purkinje cells and associated circuitry; retinal ganglion cell axons forming the optic nerve; peripheral motor/sensory axons; skeletal and extraocular muscle fibers.

Subcellular level: Mitochondria — specifically the inner mitochondrial membrane (where the m-AAA protease complex resides), affecting mitochondrial matrix protein quality control and mitochondrial DNA maintenance/nucleoid stability.

UBERON terms (suggested): UBERON:0002240 (spinal cord), UBERON:0002037 (cerebellum), UBERON:0001784 (lateral corticospinal tract) / UBERON:0002367 (corticospinal tract), UBERON:0000941 (optic nerve), UBERON:0001017 (central nervous system), UBERON:0000010 (peripheral nervous system), UBERON:0001134 (skeletal muscle tissue).

GO Cellular Component: GO:0005743 (mitochondrial inner membrane), GO:0005759 (mitochondrial matrix).

Localization/laterality: Bilateral and symmetric involvement of corticospinal tracts and cerebellar structures is characteristic (distinguishing from focal/asymmetric lesions); cerebellar atrophy in SPG7 has been reported to preferentially involve the cerebellar hemispheres rather than the vermis in at least one imaging series, and the "hot cross bun" pontine sign classically associated with MSA-C is not a typical SPG7 finding (Human Genome Variation, PMC4785587).

8. Temporal Development

• Onset: Adult-onset in the majority (mean 35.5 ± 14.3 years; typical range 20–40 years), but documented range extends from infancy to age 72 — making SPG7 a disorder with wide age-of-onset variability even within families (intrafamilial range 7–35 years documented).
• Onset pattern: Insidious/gradual, not acute or episodic.
• Progression: Slowly progressive, typically over years to decades. Pyramidal signs are usually earliest/most prevalent (89% at first exam, rising to 97%), with cerebellar features (66%→78%), dysarthria (42%→57%), dysphagia (15%→28%), amyotrophy (10%→30%), cognitive impairment (8%→19%), visual loss (7%→14%), ptosis (5%→17%), and dystonia (2%→11.5%) all increasing in frequency at longitudinal follow-up — demonstrating a cumulative, multisystem progressive course rather than a stable or episodic one.
• Disease course pattern: Chronic, progressive, lifelong; not relapsing-remitting.
• Severity milestone: Roughly one-third of affected individuals develop severe gait abnormality (wheelchair dependence in some) within 8–10 years of symptom onset.
• Remission patterns: None documented — SPG7 does not remit spontaneously; no disease-modifying treatment currently alters the progressive course.
• Critical periods: No defined developmental critical window; the length-dependent axonopathy mechanism implies risk accumulates with axon length and metabolic demand over time rather than at a discrete developmental stage, consistent with the typically adult (rather than pediatric) symptom onset despite the causal mutation being congenital.

9. Inheritance and Population

Epidemiology: - Global prevalence of all HSP forms: ~3.6 per 100,000. - Global prevalence of SPG7 specifically: ~0.22 per 100,000 (modeled estimate; BMC Neurology 2022; PMC8944001). - SPG7 accounts for 5–12% of autosomal recessive HSP cases and is recognized as a common cause of previously undiagnosed adult-onset ataxia ("SPG7 mutations are a common cause of undiagnosed ataxia," Neurology 2015).

Inheritance pattern: Autosomal recessive (biallelic pathogenic variants required in the classic model). However: - Multiple reports of apparent autosomal dominant inheritance with a single heterozygous variant have emerged, and "the possibility of autosomal dominant inheritance remains controversial" per GeneReviews. - Much of this apparent dominance is now attributed to (1) pseudodominance — an autosomal recessive disorder appearing across two generations because the founder allele (e.g., p.Ala510Val, carrier frequency ~1%) is common enough that an affected homozygote's partner is frequently also a carrier, producing affected offspring without consanguinity; and (2) "missing heritability" — a second pathogenic allele in a deep intronic or other non-coding region that is missed by exome sequencing but detectable by genome sequencing (PMC12883507; "Evidence for non-Mendelian inheritance in spastic paraplegia 7," medRxiv). - Digenic inheritance with AFG3L2 is a separate, recently described mechanism producing a related but distinct motor-neuron/cerebellar phenotype through combined heterozygosity across the two m-AAA protease genes.

Penetrance/expressivity: Full biallelic genotypes are generally considered highly, though not completely, penetrant; monoallelic (heterozygous) carriers are typically unaffected clinically but may show subtle imaging changes (reduced white matter integrity in the corpus callosum on DTI in heterozygote carriers). Expressivity is markedly variable — intrafamilial variation in age of onset (7–35 years) and in phenotype (pure spastic paraplegia through complicated spastic ataxia) is well documented even among relatives sharing the same genotype.

Genetic anticipation: Not established/reported for SPG7 (unlike triplet-repeat spinocerebellar ataxias).

Germline mosaicism: Not specifically documented in the literature reviewed for SPG7.

Founder effects / carrier frequency: p.Ala510Val is a recurrent, likely founder-associated allele with carrier frequency up to ~1% in general populations; p.Leu78Ter shows elevated frequency in South Asian gnomAD subpopulation (MAF 0.0028) and was most frequent in a Hungarian cohort — suggesting population-specific variant spectra.

Consanguinity: As an autosomal recessive disorder, parental consanguinity is a recognized risk factor and diagnostic clue (elicited in the family history per GeneReviews suggestive-findings criteria).

Population demographics: No strong ethnic-specific prevalence differences beyond the founder-allele distribution noted above; affects males and females roughly equally (no established sex-ratio skew, consistent with autosomal — not X-linked — inheritance). Age distribution reflects the adult-onset pattern described above.

10. Diagnostics

Clinical suggestive findings (GeneReviews): adult-onset (mean 35.5 years) uncomplicated or complicated spastic paraplegia, cerebellar ataxia, and/or optic nerve atrophy on exam; brain MRI with cerebellar atrophy or corticospinal/frontal white-matter changes on DTI; family history compatible with autosomal recessive inheritance (affected siblings, consanguinity).

Establishing the diagnosis: Biallelic pathogenic SPG7 variants identified by molecular genetic testing in a proband with suggestive findings.

Molecular genetic testing: - Multigene panel (SPG7 + other HSP genes) — first-line, focused. - Exome sequencing — detects >90% of pathogenic variants (option when panel is uninformative or phenotype is broad). - Genome sequencing — recommended when only one pathogenic allele is found by exome, to detect deep intronic/non-coding variants. - Deletion/duplication analysis (qPCR, long-range PCR, MLPA, targeted array) — needed for the <10% of alleles that are CNVs.

Imaging: - Brain MRI: cerebellar atrophy (reported as preferentially hemispheric rather than vermian in some series) and/or cortical atrophy; diffusion tensor imaging shows white matter changes in frontal lobes, corticospinal tracts, and brainstem. - The "hot cross bun" pontine sign (classic for MSA-C) is not a typical SPG7 finding, aiding radiological differentiation.

Laboratory/histopathology: - Skeletal muscle biopsy in severely affected individuals: ragged-red fibers and cytochrome c oxidase (COX)-deficient fibers, reflecting secondary mitochondrial dysfunction and multiple mtDNA deletions (up to 38–97% heteroplasmy in individual respiratory-deficient fibers). - Optical coherence tomography (OCT): useful for detecting subclinical optic neuropathy.

Differential diagnosis: Other AR/AD-HSP subtypes; spinocerebellar ataxias (SCA1, 2, 3, 6, 7, 17; DRPLA); AFG3L2-related autosomal recessive SCA (shares the same pathway); other mitochondrial disorders with overlapping ptosis/ophthalmoplegia/optic atrophy (e.g., POLG-related disease, which also causes multiple mtDNA deletions); treatable mimics such as dopa-responsive dystonia and specific metabolic disorders should be excluded given management implications.

Screening: No population newborn-screening program exists (adult-onset disorder); carrier/cascade testing and prenatal/preimplantation genetic testing are available once family-specific variants are identified.

Suggested NCIT terms: NCIT:C15709 (Genetic Testing) generally; specific molecular diagnostic procedures map to NCIT terms for exome sequencing, genome sequencing, and muscle biopsy as applicable.

11. Outcome/Prognosis

• Survival/mortality: SPG7 is generally not associated with reduced life expectancy from the core neurodegenerative process itself; disability rather than mortality is the primary burden. No specific survival/mortality statistics were located in the sources reviewed (consistent with a slowly progressive, non-lethal neurodegenerative disorder in most cases, though secondary complications of severe disability — e.g., aspiration from dysphagia — could contribute to morbidity/mortality risk in advanced disease).
• Morbidity/functional outcomes: Progressive gait impairment, with severe gait abnormality in ~1/3 of patients by 8–10 years post-onset; a subset become wheelchair-dependent. Multisystem morbidity accumulates over the disease course (see §3/§8 frequency table): dysarthria, dysphagia (aspiration risk), amyotrophy, cognitive impairment, visual loss, ptosis, and dystonia.
• Complications: Aspiration pneumonia risk from dysphagia; bladder dysfunction complications (UTIs); orthopedic complications (contractures, scoliosis, pes cavus) from chronic spasticity/gait abnormality; social/cognitive impact from cerebello-cortical circuit dysfunction affecting attention, executive function, and social cognition.
• Prognostic factors: Genotype correlates with phenotype trajectory — biallelic loss-of-function variants predict a more pyramidal/optic-atrophy-predominant, potentially more severe course; missense variants (notably p.Ala510Val) correlate with a more cerebellar-ataxia-predominant course with somewhat later onset.
• Quality of life measurement: No SPG7-specific validated QoL instrument identified; standardized ataxia severity scales (SARA, ICARS, BARS) are used for longitudinal tracking rather than generic QoL tools in the surveillance framework.

12. Treatment

No disease-modifying cure or specific drug therapy exists. Management is entirely supportive and multidisciplinary, involving neurology, ophthalmology, occupational/physical therapy, physiatry, orthopedics, nutrition, speech-language pathology, urology, social work, psychology, and clinical genetics.

Pharmacotherapy for spasticity (symptomatic, not disease-modifying): - Oral antispasticity agents: baclofen, tizanidine, dantrolene, diazepam (NCIT:C529 Baclofen, general pharmacotherapy class NCIT:C15986). - Botulinum toxin injections for focal spasticity. - Intrathecal baclofen pump for severe, refractory spasticity.

Rehabilitative/supportive care: - Physical therapy: balance exercises, gait training, muscle strengthening (NCIT:C15302, Physical Therapy). - Occupational therapy: adaptive devices (weighted utensils, dressing aids) (NCIT:C15302-adjacent). - Mobility aids: canes, walkers, motorized wheelchairs; home modifications (grab bars, ramps). - Speech-language therapy for dysarthria; augmentative/alternative communication evaluation. - Dysphagia management: feeding therapy, video esophagram-guided diet modification, gastrostomy tube for high aspiration risk. - Vision: corrective lenses, prisms, low-vision services for optic atrophy. - Bladder management: antimuscarinics, beta-3 agonists, botulinum toxin per urology. - Orthopedic: orthotic devices for pes cavus/scoliosis. - Cognitive/psychiatric: standard pharmacotherapy and psychotherapy/neuropsychological rehabilitation as needed.

Experimental/investigational approaches: - Pharmacological rescue studies in patient-derived iPSC neurons (high-throughput screening) have identified small molecules that reverse SPG7-associated mitochondrial and neuronal phenotypic defects in vitro — an early-stage discovery platform, not yet a clinical therapy (Frontiers Neuroscience 2023, PMC10520970). - Digital-motor outcome measures are being developed specifically as candidate endpoints for future SPG7 clinical trials, reflecting active trial-readiness research even though no SPG7-specific disease-modifying trial was identified as completed/ongoing ("Patient-Relevant Digital-Motor Outcomes for Clinical Trials in Hereditary Spastic Paraplegia Type 7," Neurology 2024). - Coenzyme Q10/mitochondrial cofactor supplementation strategies have been trialed in other mitochondrial diseases (e.g., NCT00432744, Phase III CoQ10 in mitochondrial disease; NCT01126697, CoQ10 + lisinopril in muscular dystrophies) but no SPG7-specific CoQ10/idebenone trial was located in this search — this represents a plausible but currently unvalidated extrapolated intervention for the SPG7 mitochondrial mechanism. - No approved gene therapy, cell therapy, or targeted molecular therapy currently exists for SPG7 in humans (an experimental intramuscular viral delivery of paraplegin rescued peripheral axonopathy in the mouse model — a proof-of-concept gene-replacement study, not yet translated to human trials — JCI 2005).

Genotype-informed considerations: No current pharmacogenomic (CPIC/PharmGKB) guidance specific to SPG7 was identified.

13. Prevention

• Primary prevention: Not applicable in the traditional sense (no modifiable environmental cause); the relevant primary-prevention lever is genetic: carrier screening and reproductive genetic counseling in families/populations with known pathogenic alleles (notably relevant given the ~1% carrier frequency of p.Ala510Val).
• Secondary prevention: Early molecular diagnosis via genetic testing in individuals with suggestive adult-onset spastic ataxia/optic atrophy enables earlier initiation of supportive/rehabilitative care and surveillance, and informs family counseling before further affected pregnancies occur.
• Genetic counseling: Sibling recurrence risk 25% (affected) / 50% (carrier) / 25% (unaffected, non-carrier) when both parents are known heterozygotes; offspring of an affected individual are obligate heterozygous carriers (and could be at risk of being affected if the partner also carries a pathogenic allele, given founder-allele carrier frequency). Prenatal and preimplantation genetic testing are available once family-specific variants are identified.
• Screening programs: No population-based newborn screening exists for SPG7 (adult-onset, non-emergent phenotype); carrier screening is family/variant-specific rather than population-panel-based at this time, though its relatively high founder-allele carrier frequency could support future consideration in expanded carrier panels.
• Behavioral/lifestyle interventions: No specific risk-reducing lifestyle intervention is established; general good mitochondrial-health practices (avoidance of mitochondrial-toxic drugs where possible, regular exercise/physical therapy to maintain function) are reasonable extrapolated supportive measures rather than evidence-based disease-modifying prevention.
• Public health/environmental interventions: Not applicable — SPG7 has no environmental or infectious trigger requiring public health intervention.

14. Other Species / Natural Disease

• Taxonomy: SPG7 orthologs show stringent 1:1 orthology across vertebrates: human (Homo sapiens, NCBITaxon:9606), mouse (Mus musculus, NCBITaxon:10090), rat (Rattus norvegicus, NCBITaxon:10116), and zebrafish (Danio rerio, NCBITaxon:7955; UniProt E7F2S4).
• Gene orthologs: Mouse Spg7 (MGI:2385906); Drosophila paraplegin ortholog (studied via null-mutant/deletion models).
• Natural disease in other species: No naturally occurring companion-animal or wildlife SPG7-orthologous disease was identified in this search (OMIA not specifically queried/found with a hit); the available animal data are all engineered/induced models (knockouts), not natural disease.
• Comparative biology: The m-AAA protease mechanism (paraplegin-AFG3L2 complex) and its role in mitochondrial protein quality control, calcium homeostasis, and axonal maintenance is evolutionarily conserved from yeast (yeast m-AAA protease orthologs originally characterized the pathway) through Drosophila, zebrafish, mouse, and human — underscoring deep conservation of the disease mechanism.
• Zoonotic potential/cross-species transmission: Not applicable — SPG7 is a non-infectious, genetic, non-transmissible disorder.

15. Model Organisms

Research applications: These models collectively support study of (1) the temporal sequence of mitochondrial dysfunction preceding axonal degeneration, (2) axonal transport impairment as a proximate mechanism, (3) cell-autonomous (neuronal) vs. non-cell-autonomous (astrocytic) contributions, (4) digenic/synergistic genetic interactions (SPG7+AFG3L2), and (5) small-molecule/gene-therapy rescue strategies as a translational pipeline toward future SPG7 clinical trials.

Summary of Key Ontology Term Suggestions for KB Curation

Sources

• SPG7-Related Neurologic Disorder – GeneReviews (NCBI Bookshelf NBK1107)
• OMIM #607259 – Spastic Paraplegia 7, Autosomal Recessive
• OMIM #602783 – SPG7 Matrix AAA Peptidase Subunit, Paraplegin
• GARD – Hereditary spastic paraplegia 7
• NIH GTR – Hereditary spastic paraplegia 7
• MalaCards – Spastic Paraplegia 7, Autosomal Recessive
• Expanding the Phenotypic Spectrum of SPG7 Rare Damaging Variants: Insights From a Hungarian Cohort (PMC12215234)
• A Novel SPG7 Gene Pathogenic Variant in a Cypriot Family (PMC8793673)
• Digenic inheritance of mutations in SPG7 and AFG3L2 causes motor neuron and cerebellar disorders – BMC Medicine 2025
• Digenic SPG7/AFG3L2 – medRxiv preprint
• An integrated modelling methodology for estimating global incidence and prevalence of HSP subtypes SPG4, SPG7, SPG11, SPG15 – BMC Neurology 2022 / PMC8944001
• SPG7 mutations are a common cause of undiagnosed ataxia – Neurology 2015
• Evidence for non-Mendelian inheritance in spastic paraplegia 7 – medRxiv
• Identification of an additional deep intronic splice variant prompts critical evaluation of SPG7 inheritance (PMC12883507)
• Loss of the Drosophila m-AAA mitochondrial protease paraplegin – Cell Death & Disease 2018 / PMC5833341
• Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport – JCI
• Intramuscular viral delivery of paraplegin rescues peripheral axonopathy – JCI 2005
• m-AAA proteases, mitochondrial calcium homeostasis and neurodegeneration – Cell Research (PMC5835776)
• Astrocyte-specific deletion of the mitochondrial m-AAA protease reveals glial contribution to neurodegeneration (PMC6618114)
• Predominant cerebellar phenotype in spastic paraplegia 7 (SPG7) – Human Genome Variation (PMC4785587)
• Novel genotype-phenotype and MRI correlations in a large cohort of patients with SPG7 mutations – Neurology Genetics (PMC6244025)
• Cerebello-Cortical Alterations Linked to Cognitive and Social Problems in SPG7 (PMC7053515)
• Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance – Brain 2014
• Spastic Paraplegia Type 7 Is Associated with Multiple Mitochondrial DNA Deletions (PMC3899233)
• Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells (PMC7469654)
• Pharmacological rescue of mitochondrial and neuronal defects in SPG7 patient neurons using high throughput assays – Frontiers Neuroscience 2023 (PMC10520970)
• Patient-Relevant Digital-Motor Outcomes for Clinical Trials in Hereditary Spastic Paraplegia Type 7 – Neurology 2024
• Ataxia UK – SPG7 patient information PDF
• ClinicalTrials.gov NCT00432744 – Phase III Trial of Coenzyme Q10 in Mitochondrial Disease
• ClinicalTrials.gov NCT01126697 – Coenzyme Q10 and Lisinopril in Muscular Dystrophies
• UniProt E7F2S4 – zebrafish spg7 ortholog
• MGI:2385906 – mouse Spg7 gene detail

Reference Validation

Checked with linkml-reference-validator 0.2.1.

4 of 17 references resolved; the rest could not be looked up either way.